New option listings for January 24th include Immix Biopharma Inc (IMMX), Myomo (MYO), and Neuropace Inc (NPCE).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMMX:
- Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
- Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
- Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
- Immix Biopharma reports 100% ORR for CAR-T NXC-201 in r/r AL amyloidosis
- Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
